2308 related articles for article (PubMed ID: 35958598)
1. Comprehensive
Xu T; Xu W; Zheng Y; Li X; Cai H; Xu Z; Zou Q; Yu B
Front Immunol; 2022; 13():931906. PubMed ID: 35958598
[TBL] [Abstract][Full Text] [Related]
2. Integrative transcriptional characterization of cell cycle checkpoint genes promotes clinical management and precision medicine in bladder carcinoma.
Shi WW; Guan JZ; Long YP; Song Q; Xiong Q; Qin BY; Ma ZQ; Hu Y; Yang B
Front Oncol; 2022; 12():915662. PubMed ID: 36033441
[TBL] [Abstract][Full Text] [Related]
3. Identification of a Nuclear Mitochondrial-Related Multi-Genes Signature to Predict the Prognosis of Bladder Cancer.
Jiang X; Xia Y; Meng H; Liu Y; Cui J; Huang H; Yin G; Shi B
Front Oncol; 2021; 11():746029. PubMed ID: 34692528
[TBL] [Abstract][Full Text] [Related]
4. Mitochondrial-Related Transcriptome Feature Correlates with Prognosis, Vascular Invasion, Tumor Microenvironment, and Treatment Response in Hepatocellular Carcinoma.
Wang Y; Song F; Zhang X; Yang C
Oxid Med Cell Longev; 2022; 2022():1592905. PubMed ID: 35535359
[TBL] [Abstract][Full Text] [Related]
5. Construction of a novel mRNA-signature prediction model for prognosis of bladder cancer based on a statistical analysis.
Li J; Cao J; Li P; Yao Z; Deng R; Ying L; Tian J
BMC Cancer; 2021 Jul; 21(1):858. PubMed ID: 34315402
[TBL] [Abstract][Full Text] [Related]
6. Construction and validation of a bladder cancer risk model based on autophagy-related genes.
Shen C; Yan Y; Yang S; Wang Z; Wu Z; Li Z; Zhang Z; Lin Y; Li P; Hu H
Funct Integr Genomics; 2023 Jan; 23(1):46. PubMed ID: 36689018
[TBL] [Abstract][Full Text] [Related]
7. Overweight/obesity-related transcriptomic signature as a correlate of clinical outcome, immune microenvironment, and treatment response in hepatocellular carcinoma.
Feng NN; Du XY; Zhang YS; Jiao ZK; Wu XH; Yang BM
Front Endocrinol (Lausanne); 2022; 13():1061091. PubMed ID: 36714595
[TBL] [Abstract][Full Text] [Related]
8. Identification and validation of a dysregulated TME-related gene signature for predicting prognosis, and immunological properties in bladder cancer.
Shen C; Chai W; Han J; Zhang Z; Liu X; Yang S; Wang Y; Wang D; Wan F; Fan Z; Hu H
Front Immunol; 2023; 14():1213947. PubMed ID: 37965307
[TBL] [Abstract][Full Text] [Related]
9. Transcriptomic correlates of cell cycle checkpoints with distinct prognosis, molecular characteristics, immunological regulation, and therapeutic response in colorectal adenocarcinoma.
Wang H; Wang W; Wang Z; Li X
Front Immunol; 2023; 14():1291859. PubMed ID: 38143740
[TBL] [Abstract][Full Text] [Related]
10. Derivation and Comprehensive Analysis of Aging Patterns in Patients with Bladder Cancer.
Wang B; Tong F; Zhai C; Wang L; Liu Y; Wang J
Dis Markers; 2021; 2021():3385058. PubMed ID: 34721733
[TBL] [Abstract][Full Text] [Related]
11. FGFR3 mutation characterization identifies prognostic and immune-related gene signatures in bladder cancer.
Xu PH; Chen S; Wang Y; Jin S; Wang J; Ye D; Zhu X; Shen Y
Comput Biol Med; 2023 Aug; 162():106976. PubMed ID: 37301098
[TBL] [Abstract][Full Text] [Related]
12. Prognostic model development and molecular subtypes identification in bladder urothelial cancer by oxidative stress signatures.
Dong Y; Wu X; Xu C; Hameed Y; Abdel-Maksoud MA; Almanaa TN; Kotob MH; Al-Qahtani WH; Mahmoud AM; Cho WC; Li C
Aging (Albany NY); 2024 Feb; 16(3):2591-2616. PubMed ID: 38305808
[TBL] [Abstract][Full Text] [Related]
13. An amino acid metabolism-based seventeen-gene signature correlates with the clinical outcome and immune features in pancreatic cancer.
Hao J; Zhou C; Wang Z; Ma Z; Wu Z; Lv Y; Wu R
Front Genet; 2023; 14():1084275. PubMed ID: 37333498
[No Abstract] [Full Text] [Related]
14. Pan-cancer analysis identifies proteasome 26S subunit, ATPase (PSMC) family genes, and related signatures associated with prognosis, immune profile, and therapeutic response in lung adenocarcinoma.
Jia H; Tang WJ; Sun L; Wan C; Zhou Y; Shen WZ
Front Genet; 2022; 13():1017866. PubMed ID: 36699466
[No Abstract] [Full Text] [Related]
15. A mitophagy-related gene signature associated with prognosis and immune microenvironment in colorectal cancer.
Zhang C; Zeng C; Xiong S; Zhao Z; Wu G
Sci Rep; 2022 Nov; 12(1):18688. PubMed ID: 36333388
[TBL] [Abstract][Full Text] [Related]
16. Identification and characterization of a 25-lncRNA prognostic signature for early recurrence in hepatocellular carcinoma.
Fu Y; Wei X; Han Q; Le J; Ma Y; Lin X; Xu Y; Liu N; Wang X; Kong X; Gu J; Tong Y; Wu H
BMC Cancer; 2021 Oct; 21(1):1165. PubMed ID: 34717566
[TBL] [Abstract][Full Text] [Related]
17. TFRC, associated with hypoxia and immune, is a prognostic factor and potential therapeutic target for bladder cancer.
Tang R; Wang H; Liu J; Song L; Hou H; Liu M; Wang J; Wang J
Eur J Med Res; 2024 Feb; 29(1):112. PubMed ID: 38336764
[TBL] [Abstract][Full Text] [Related]
18. A Novel Aging-Related Prognostic lncRNA Signature Correlated with Immune Cell Infiltration and Response to Immunotherapy in Breast Cancer.
Liu Z; Ren C; Cai J; Yin B; Yuan J; Ding R; Ming W; Sun Y; Li Y
Molecules; 2023 Apr; 28(8):. PubMed ID: 37110517
[TBL] [Abstract][Full Text] [Related]
19. An Unfolded Protein Response Related Signature Could Robustly Predict Survival Outcomes and Closely Correlate With Response to Immunotherapy and Chemotherapy in Bladder Cancer.
Zhang F; Feng D; Wang X; Gu Y; Shen Z; Yang Y; Wang J; Zhong Q; Li D; Hu H; Han P
Front Mol Biosci; 2021; 8():780329. PubMed ID: 35004850
[No Abstract] [Full Text] [Related]
20. A novel signature incorporating lipid metabolism- and immune-related genes to predict the prognosis and immune landscape in hepatocellular carcinoma.
Yang T; Luo Y; Liu J; Liu F; Ma Z; Liu G; Li H; Wen J; Chen C; Zeng X
Front Oncol; 2023; 13():1182434. PubMed ID: 37346073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
